机译:由于ARAF新型功能突变而具有晚期淋巴异常的儿童在用MEK抑制剂治疗后具有缓解
Childrens Hosp Philadelphia Ctr Appl Genom Philadelphia PA 19104 USA;
Childrens Hosp Philadelphia Ctr Appl Genom Philadelphia PA 19104 USA;
Childrens Hosp Philadelphia Ctr Appl Genom Philadelphia PA 19104 USA;
Childrens Hosp Philadelphia Ctr Appl Genom Philadelphia PA 19104 USA;
Childrens Hosp Philadelphia Res Inst Zebrafish Core Facil Philadelphia PA 19104 USA;
Childrens Hosp Philadelphia Ctr Lymphat Imaging &
Intervent Philadelphia PA 19104 USA;
Childrens Hosp Philadelphia Ctr Appl Genom Philadelphia PA 19104 USA;
Seattle Childrens Hosp Div Craniofacial Med Seattle WA USA;
Univ Penn Sch Med Dept Pediat Philadelphia PA 19104 USA;
Univ Penn Sch Med Dept Pediat Philadelphia PA 19104 USA;
Childrens Hosp Philadelphia Ctr Lymphat Imaging &
Intervent Philadelphia PA 19104 USA;
Childrens Hosp Philadelphia Ctr Appl Genom Philadelphia PA 19104 USA;
机译:由于ARAF新型功能突变而具有晚期淋巴异常的儿童在用MEK抑制剂治疗后具有缓解
机译:MEK抑制剂RO4987655(CH4987655)在某些患有RAS-RAF突变的晚期癌症患者中的I期扩展和药效学研究
机译:PIK3CD中功能增益突变的患者mTOR抑制剂治疗的初步数据
机译:RAF / MEK / MTOR抑制剂组合PK / PD研究的研制治疗MALDI质谱成像治疗儿科低级星形细胞瘤
机译:淋巴泵治疗可增强肺部免疫力并抑制肺部实体瘤的形成
机译:Cdc42 / Rac1 GTPase调节剂ARHGAP31的功能获得性突变导致综合征性角质层发育不全和肢体异常
机译:BRAF,MEK和PI3K / MTOR抑制剂的组合克服了由NRAS或MEK突变介导的BRAF抑制剂GSK2118436 Dabrafenib的获得性抗性